Table 2.
Adverse Events Reported in Each Trial.
| Author | Adverse events | |
|---|---|---|
| Experimental arm* | Control arm* | |
| Birling et al 25 | 10/38 (dry mouth, frequent night waking, facial skin rash, urinary urgency); | Placebo: 16/47 (not detailed) |
| Chan et al 34 | 6/45 (diarrhea, sweating, dizziness, morning sleepiness); | Placebo: 3/45 (morning sleepiness and headache) |
| Dai et al 35 | 1/30 (dyspepsia) | Placebo: 0/30; Zopiclone: 6/30 (fatigue and nausea) |
| Hu et al 36 | 1/60 (diarrhea) | Lorazepam: 2/59 (dizziness) |
| Lee et al 37 | 2/15 (leg edema, dyspepsia) | Waitlist: 0/15 |
| Moon et al 42 | Not reported | |
| Mun et al 43 | No adverse events were reported | |
| Scholey et al 44 | 11/85 (not detailed) | Placebo: 14/85 (not detailed) |
| Song et al 45 | 24/120 (constipation, loss of appetite, dizziness, abnormal liver function, sexual dysfunction) | Lorazepam: 93/120 (constipation, loss of appetite, dizziness, abnormal liver function, sexual dysfunction) |
*
Data are presented as cases with AE/group sample size.